The precise mechanism of how YAP drives TKI resistance in many cancers remains poorly understood, yet is thought to be secondary to YAP transcriptional target upregulation, such as AXL, AREG, ERBB3, and CTGF [82,83,84]. Here, YAP1 is linked to cancer.